Mental state specific: average end point scores, medium‐term (at 12 months), various scales (higher score = worse), skewed data
Study	Intervention	Mean	SD	N	Note
Psychopathology: total, end point data, BPRS
Yung‐Australia	Risperidone + CBT	14	9.3	24
Yung‐Australia	Placebo + CBT	16.5	11.1	27
Negative symptoms: attention, end point data, SANS
Yung‐Australia	Risperidone + CBT	1.7	1.6	24
Yung‐Australia	Placebo + CBT	1.8	1.9	27
Negative symptoms: total, end point data, SANS
Yung‐Australia	Risperidone + CBT	17.8	13.8	24
Yung‐Australia	Placebo + CBT	16.3	11.6	27